Novartis and GlaxoSmithKline two of the worlds top drugmakers have struck a multibilliondollar deal to join forces and reshape their businesses The deal involves swapping assets and combining their consumer health units Novartis will acquire GSKs cancer drugs business for bn bn and sell its vaccines division excluding the flu unit to GSK for bn In a separate deal Novartis has agreed to sell its animal health division to Lilly for nearly bn Novartis said the moves would help the firm focus on its key businesses The transactions mark a transformational moment for Novartis Joseph Jimenez chief executive of Novartis    They also improve our financial strength and are expected to add to our growth rates and margins immediately The deals are a part of Novartiss review of its business as it continues to face sluggish growth Novartis and GSK said that combining their overthecounter OTC units would help boost the fortunes of both the companies The combined unit will have annual revenues of bn Opportunities to build greater scale and combine high quality assets in vaccines and consumer healthcare are scarce Andrew Witty chief executive of GSK said in a statement With this transaction we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders GSK said the agreement with Novartis significantly exceeds GSKs returns criteria and the transaction would increase overall GSK revenues by bn to bn Glaxo shareholders will get a bn capital return from the proceeds of the deal the firm said The tieup between the two firms came at the same time as Canadian drugs firm   for bn bn  Allergans largest shareholder hedge fund Pershing Square run by activist investor Bill Ackman said it supported the bid  In a statement Valeant said buying Allergan would help it to drive growth creating an unrivalled platform for value creation in healthcare